Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial

The Lancet Oncology

Volumn 10, Issue 8, 2009, Pages 757-763

  Gore, Martin E ^a   Szczylik, Cezary ^b   Porta, Camillo ^c   Bracarda, Sergio ^d   Bjarnason, Georg A ^e   Oudard, Stéphane ^f   Hariharan, Subramanian ^g   Lee, Se Hoon ^h   Haanen, John ⁱ   Castellano, Daniel ^j   Vrdoljak, Eduard ^k   Schöffski, Patrick ^l   Mainwaring, Paul ^m   Nieto, Alejandra ^g   Yuan, Jinyu ^g   Bukowski, Ronald ⁿ  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b MILITARY INSTITUTE OF MEDICINE   (Poland)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^e DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^f HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^g Pfizer Ltd   (United States)

^h Seoul National University Hospital   (South Korea)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^j HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^k UNIVERSITY HOSPITAL SPLIT   (Croatia)

^l UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^m MATER ADULT HOSPITAL   (Australia)

ⁿ TAUSSIG CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

SUNITINIB;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BONE METASTASIS; BRAIN METASTASIS; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONSTIPATION; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPEPSIA; EPISTAXIS; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEADACHE; HEART FAILURE; HUMAN; HYPERTENSION; HYPOTHYROIDISM; JAUNDICE; KIDNEY CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; METASTASIS POTENTIAL; MUCOSA INFLAMMATION; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEPHRECTOMY; NEUTROPENIA; OPEN STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RASH; SKIN DISCOLORATION; STOMATITIS; THROMBOCYTOPENIA; TUMOR VOLUME; VOMITING;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; HUMANS; INDOLES; KIDNEY NEOPLASMS; PYRROLES; SURVIVAL ANALYSIS;

EID: 67651201656     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70162-7     Document Type: Article

References (31)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global Cancer Statistics, 2002. CA Cancer J Clin 55 (2005) 74-108
2. Schöffski P., Dumez H., Clement P., et al. Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review. Ann Oncol 17 (2006) 1185-1196
3. Motzer R.J., Bander N.H., and Nanus D.M. Renal-cell carcinoma. N Engl J Med 335 (1996) 865-875
4. Lam J.S., Leppert J.T., Belldegrun A.S., and Figlin R.A. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 23 (2005) 202-212
5. Amato R.J. Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens. Ann Oncol 16 (2005) 7-15
6. Janzen N.K., Kim H.L., Figlin R.A., and Belldegrun A.S. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30 (2003) 843-852
7. Faivre S., Delbaldo C., Vera K., et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor in patients with cancer. J Clin Oncol 24 (2006) 25-35
8. Abrams T.J., Lee L.B., Murray L.J., Pryer N.K., and Cherrington J.M. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Ther 2 (2003) 471-478
9. O'Farrell A.M., Abrams T.J., Yuen H.A., et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101 (2003) 3597-3605
10. O'Farrell A.M., Foran J.M., Fiedler W., et al. An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients. Clin Cancer Res 9 (2003) 5465-5476
11. Mendel D.B., Laird A.D., Xin X., et al. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9 (2003) 327-337
12. Motzer R.J., Michaelson M.D., Redman B.G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol 24 (2006) 16-24
13. Motzer R.J., Rini B.I., Bukowski R.M., et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA 295 (2006) 2516-2524
14. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 356 (2007) 115-124
15. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib versus interferon alfa in first-line treatment of patients with metastatic renal cell carcinoma. J Clin Oncol (2009) published online June 1. DOI:0:JCO.2008.20.1293v1.
16. Posner J.B., and Chernik N.L. Intracranial metastases from systemic cancer. Adv Neurol 19 (1978) 579-592
17. Saitoh H. Distant metastasis of renal adenocarcinoma. Cancer 48 (1981) 1487-1491
18. Culine S., Bekradda M., Kramar A., Rey A., Escudier B., and Droz J.P. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 83 (1998) 2548-2553
19. Motzer R.J., Bacik J., Schwartz L.H., et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 22 (2004) 454-463
20. Motzer R.J., Bacik J., Murphy B.A., Russo P., and Mazundar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20 (2002) 289-296
21. Choueiri T.K., Garcia J.A., Elson P., et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110 (2007) 543-550
22. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
23. Porta C., Szczylik C., Bracarda S., et al. Short- and long-term safety with sunitinib in an expanded access trial in metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 26 (2008) 5114
24. SUTENT® (sunitinib malate) prescribing information. http://www.sutent.com (accessed May 2009).
25. Houk BE, Bello CL, Demetri GD, et al. Comparative efficacy of sunitinib administered on an intermittent or a continuous daily dosing schedule in metastatic renal cell carcinoma (mRCC) and gastrointestinal stromal tumor (GIST) patients predicted using population PK approaches. Proceedings of the 99th Annual Meeting of the American Association for Cancer Research; San Diego, CA, USA; Apr 12-16, 2008. Abstr 5828.
26. Motzer R.J., Bacik J., Mariani T., et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 20 (2002) 2376-2381
27. Medioni J., Cojocarasu O., Belcaceres J.L., Halimi P., and Oudard S. Complete cerebral response with sunitinib for metastatic renal cell carcinoma. Ann Oncol 18 (2007) 1282-1283
28. Negrier S. Case Report 3. Sunitinib malate in patients with cerebellar metastases. Eur J Cancer Suppl 5 (2007) 32-34
29. Helgason H.H., Mallo H.A., Droogendijk H., et al. Brain metastases in patients with renal cell cancer receiving new targeted treatment. J Clin Oncol 26 (2008) 152-154
30. Patyna S., and Peng J. Distribution of sunitinib and its active metabolite in brain and spinal cord tissue following oral or intravenous administration in rodents and monkeys. Eur J Cancer 4 (2006) 21
31. Hariharan S., Szczylik C., Porta C., et al. Sunitinib in metastatic renal cell carcinoma patients with brain metastases: data from an expanded access trial. Proc Am Soc Clin Oncol 26 (2008) 5094